title: Plasma myeloperoxidase level and peripheral arterial disease.
abstract: BACKGROUND
  Myeloperoxidase (MPO) is involved in a multitude of inflammatory processes involving oxidative modification of soluble components and cellular surfaces. Thus, MPO plays a key role in promoting atherosclerosis via oxidative stress by modification of both high- and low-density lipoprotein and production of other bioactive molecules. A polymorphism (MPO 463G>A, rs2333227) results in different expression rates of MPO. We aimed to assess whether MPO could be of clinical use as a risk marker for vascular disease in a high-risk group.
  
  
  METHODS
  Plasma MPO levels of 406 patients suffering from peripheral arterial disease (PAD) were measured on an Abbott Architect i2000sr and grouped into patients with high (>115 ng/mL) and low (< 115 ng/mL) MPO levels. Genotyping of rs2333227 was performed on an ABI TaqMan 7900HT RT-PCR thermocycler.
  
  
  RESULTS
  The relative risk of major adverse cardiovascular events (MACE) for patients with high plasma MPO is 1.2 (95%CI: 1.038-1.377, P < 0.05), initial event-free periods in male patients are significantly longer in patients with MPO <115 ng/mL (mean = 875 days compared with mean = 734 days, P < 0.05) In smokers, an increased hazard ratio was computed for patients with high MPO levels (HR = 3.127, 95%CI: 1.258-7.772, P < 0.05). Effects of MPO [-463A] allele on initial MACE-free intervals did not persist after multivariate analysis.
  
  
  CONCLUSIONS
  Hence, we suggest consideration of plasma MPO for risk stratification of MACE in patients with PAD. In contrast, MPO-463G>A is not an independent risk factor for MACE in patients suffering from PAD.
authors.affiliation: Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria.
authors.forename: Helmuth
authors.initials: H
authors.lastname: Haslacher
authors.forename: Thomas
authors.initials: T
authors.lastname: Perkmann
authors.forename: Julia
authors.initials: J
authors.lastname: Gruenewald
authors.forename: Markus
authors.initials: M
authors.lastname: Exner
authors.forename: Georg
authors.initials: G
authors.lastname: Endler
authors.forename: Vanessa
authors.initials: V
authors.lastname: Scheichenberger
authors.forename: Oswald
authors.initials: O
authors.lastname: Wagner
authors.forename: Martin
authors.initials: M
authors.lastname: Schillinger
mesh_terms: D000368:Aged; D050197:Atherosclerosis / Q000201:enzymology / Q000235:genetics; D015415:Biomarkers / Q000097:blood*; D002318:Cardiovascular Diseases / Q000201:enzymology / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000201:enzymology* / Q000235:genetics; D009195:Peroxidase / Q000097:blood* / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D011237:Predictive Value of Tests; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D009195:Peroxidase